Qubit Pharmaceuticals, a fast-growing innovative start-up, is at the forefront of chemistry research and numerical simulation, with an ambitious goal: to accelerate the discovery of new molecules and generate drug candidates from complex molecular data. Qubit Pharmaceuticals' Machine Learning team, composed of specialized researchers and developers, called upon MARGO to develop and deploy Machine Learning algorithms (Xgboost, Lightgbm, Catboost, GNN, NN) to optimize and automate the molecular discovery process.
-
17 Apr 2026
Qubit Pharmaceuticals: Revolutionising Molecular Research with Artificial Intelligence
Context: Why has anticipating demand become strategic?
Challenges: Optimizing molecular research to become a leader in Medical Innovation
The main challenge for Qubit Pharmaceuticals is to improve the efficiency of the molecule generation process by making exploration faster, more exhaustive, and better guided. This involves reducing the need for costly laboratory tests and enabling broader and more precise molecular exploration.
The objectives are as follows:
Optimize the new molecule generation tool through Machine Learning models (Xgboost, Lightgbm, Catboost, GNN, NN).
Explore molecular space in a more exhaustive, rapid, and targeted manner.
Develop a plug-and-play tool accessible to all research teams for large-scale adoption.
Metrics:
- Convergence speed: Measurement of the time required for models to reach an optimal solution. Improving this metric has increased the efficiency of the molecule generation process.
- Exploration diversity: Key indicator for measuring the variety of generated molecules. The goal is to find a balance between exhaustive and targeted exploration of molecules.
- Repeatability: Measurement of the ability to reproduce the results obtained, ensuring the robustness and reliability of the developed models.
- Chemical prediction accuracy: Evaluation of the models' ability to correctly predict the chemical properties of molecules, an essential criterion for optimizing the drug-candidate selection process.
These metrics make it possible to track the effectiveness of machine learning models and ensure that results align with the project's objectives.
MARGO's Response: Optimization of molecular exploration and development of Machine Learning algorithms
MARGO deployed a solution integrating machine learning models, such as Graph Neural Networks (GNN) and Reinforcement Learning (RL) approaches, to more effectively predict the chemical properties of molecules.
From data to discovery: tailor-made support
Working closely with Qubit Pharmaceuticals' internal teams, MARGO has:
- Optimized molecular exploration by combining machine learning techniques and graph theory to model molecules and accelerate their generation.
- Implemented an evolving internal ML package, allowing for rapid and smooth integration of new discoveries into the research process.
- Created quality metrics to measure convergence speed, exploration diversity, and repeatability, thereby guaranteeing the efficiency and reliability of the discovery process.
Innovation at the heart of the project
This project perfectly illustrates MARGO's ability to integrate cutting-edge technologies to meet complex challenges. The use of Graph Neural Networks for molecular exploration, a new and promising approach, makes it possible to fully exploit the potential of molecular data by refining predictions for new viable molecules.
ROI
MARGO's intervention generated significant benefits:
Time savings and reduction in research costs Automating molecule generation reduces the number of laboratory tests and focuses resources on the most promising molecules.
Acceleration of drug research Thanks to predictive models, Qubit can identify drug candidates faster, reducing time-to-market.
Increased efficiency of internal processes Automation of internal tasks, such as document parsing, improves the ML team's productivity and allows researchers to focus on higher value-added tasks.
Scalability of the ML system The updated ML package is now stable, flexible, and easily deployable, allowing Qubit to respond more quickly to new research challenges.
Conclusion: Qubit Pharmaceuticals has reached a key milestone in the research of new molecules
MARGO's AI expertise has allowed Qubit Pharmaceuticals to reach an important milestone in optimizing its processes for generating new molecules. This molecule generation project, now optimized through machine learning methods, has become a true strategic lever for accelerating scientific discoveries.
The molecule generation tool is now ready to be deployed on a large scale and will be accessible to all Qubit teams. This project is part of a broader vision for innovation, with potential new applications in quantum physics, chemistry, and medicine.
Are you facing similar challenges? Contact us!
Through the use of machine learning technologies and close collaboration with Qubit Pharmaceuticals' chemists and researchers, MARGO has made the generation of new molecules faster, more reliable, and more cost-effective. This partnership with Qubit confirms MARGO's expertise in implementing cutting-edge AI solutions, particularly in complex sectors such as scientific and pharmaceutical research.
Transform your challenges into opportunities with innovative and tailor-made solutions!
What was Qubit Pharmaceuticals' main objective?
Qubit Pharmaceuticals sought to accelerate the discovery of new molecules and generate drug candidates from complex molecular data, using advanced machine learning models.
What were the main challenges encountered?
The challenge was to make molecular exploration faster, more exhaustive, and better targeted, while reducing costly laboratory tests and facilitating the large-scale adoption of AI tools.
What technologies were deployed by MARGO?
MARGO's teams integrated Machine Learning models such as Graph Neural Networks (GNN), Reinforcement Learning (RL), as well as Xgboost, LightGBM, and Catboost to model and predict the chemical properties of molecules.
What did the collaboration between Qubit and MARGO consist of?
MARGO worked closely with internal teams to optimize molecular exploration, develop a scalable internal ML package, and create quality metrics ensuring model reliability and performance.
What concrete benefits were obtained?
The project resulted in reduced research costs, faster time-to-market for new drugs, improved internal productivity, and a more flexible, scalable ML system.
What metrics were used to measure performance?
Convergence speed, exploration diversity, repeatability of results, and chemical prediction accuracy were used to evaluate the efficiency and robustness of the AI models.
What is the overall impact of the project?
This project marks a key step for Qubit Pharmaceuticals in modernizing molecular research and paves the way for new applications in chemistry, medicine, and quantum physics.
How does MARGO support other companies?
Through its expertise in AI and the industrialization of Machine Learning models, MARGO helps other organizations overcome similar challenges by optimizing their research, analysis, and innovation processes.
